Glaxo Pleads Guilty to Unapproved Marketing of Paxil & Wellbutrin: Will Pay $3 Billion Penalty
July 2, 2012
In agreeing to settle the largest case of health care fraud in U.S. history, GlaxoSmithKline pled guilty today to marketing Paxil for teens and children and to advertising Wellbutrin for weight loss and sexual dysfuntion. Glaxo will pay $1 billion in criminal fines and $2 billion in civil fines for activities such as distributing a misleading journal article and providing kickbacks to doctors. “Today’s historic settlement is a major milestone in our efforts to stamp out health care fraud,” said the deputy secretary of health and human services in a statement.
Related Item:
GlaxoSmithKline settles healthcare fraud case for $3 billion
Glaxo Agrees to Pay $3 Billion in Fraud Settlement
Add a couple more zeros and we will be getting somewhere!
Report comment